Orphan Drug Designation
European Medicines Agency Issues Positive Opinion on Orphan Drug Designation for Tamibarotene for the Treatment of MDS
Cecilia BrownMyelodysplastic Syndromes | November 16, 2022
The FDA granted Orphan Drug Designation to tamibarotene for the treatment of MDS in February 2022.
Read More
FDA Clears IND Application for Humanized Gamma-Delta Bispecific Antibody
Kerri FitzgeraldAcute Myeloid Leukemia | November 16, 2022
The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...
Read More
Tasquinimod Granted Orphan Drug Designation for Myelofibrosis
Leah LawrenceMyelofibrosis | February 8, 2024
Tasquinimod is an oral immunomodulatory and antiangiogenic investigational treatment.
Read More
Advertisement
HM43239 Granted Fast Track Designation for AML
Leah LawrenceAcute Myeloid Leukemia | February 2, 2023
The oral treatment from Aptose Biosciences is in development for relapsed/refractory AML with FLT3 mutation.
Read More
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |